Glaxosmithkline Intellectual Property Development Limited

Medshine Discovery Inc.

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology (shijiazhuang) Co., Ltd.

Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd.

Shanghai Hansoh Biomedical Co., Ltd.

Guangdong Raynovent Biotech Co., Ltd.

Cstone Pharmaceuticals

Cstone Pharmaceuticals (shanghai) Co., Ltd.

Cstone Pharmaceutical (suzhou) Co., Ltd.

Wuxi Life Fountain Biotech Co., Ltd

Chia Tai Tianqing Pharmaceutical Group Go., Ltd.

Cstone Pharmaceuticals Co., Ltd.

Cspc Zhongqi Pharmaceutical Technology Co., Ltd.

Zhen Gong

Jian Li

Shuhui Chen

Chengde Wu

Haiying He

Mui Cheung

Jie Li

Hilary Schenck Eidam

Huiping Amy Guan

Zhigan Jiang

Chen Zhang

Xing Liu

Yan Wang

Yong Liang Liu

Xiao Xun Zhang

Xiquan Zhang

Kevin X Chen

Wentao Wu

Wenyuan Qian

Zhengxia Chen

Jian Xiong

Chaofeng Long

Xiaoxin Chen

Xin Tian

Zhiqiang Liu

Aiming Zhang

Jun Lin

Changqing Wei

Cheng Xie

Qinghua Mao

Zhixiang Li

Meibi Dai

Michael P DeMartino

Zhiliu Zhang

Haiying Yang

Haiyu Yu

Donghui Qin

Michael P Demartino

Chunli Shen

Xiongbin Xu

Jiaqiang Dong

Yonggang Liao

Jian Qin

Xiaoping Zheng

Jianhua Xia

Yong Huang

Fangfang Jin

Yikai Wang

Zhiliang Yuan

Chaonan Liu

Xuejin Zhang

Zhulian Jiang

Leilei Gao

Kaushik Raha

Wensheng Yu

Xinxian Deng

Xiao Zhang

Yong Liu

Amy Huiping Guan

A nitrogen-containing heterocyclic derivative inhibitor, a preparation method therefor and the use thereof. Specifically disclosed are a compound as represented by general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof as an inhibitor in treating diseases such as cardiovascular and cerebrovascular diseases, wherein the definition of each substituent in the general formula (I) are the same as those defined in the description.

Nitrogen-containing heterocyclic derivative inhibitor, preparation method therefor and use thereof

A series of pyrazolopymidine derivatives, and use thereof in the preparation of a medicament for treating disease associated with FGFR and c-Met. The pyrazolopymidine derivative is a compound represented by formula (I), a tautomer, or a pharmaceutically acceptable salt thereof.

Azaindole derivative and use thereof as FGFR and C-Met inhibitor

The present invention relates to a class of TrkA inhibitors and an application thereof in the preparation of a drug for the treatment of diseases associated with TrkA. The present invention specifically discloses compounds represented by formula (I) and formula (II), tautomer thereof or pharmaceutically acceptable salts thereof.

Pyrrolidinyl urea derivatives and application thereof in TrkA-related diseases

The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

2,3-dihydro-1H-pyrrolizine-7-formamide derivative and application thereof

Disclosed are a thieno[2,3-c]pyridazin-4(1H)-one derivative as an ACC1 or ACC2 inhibitor and an application thereof in preparing a drug as an ACC1 or ACC2 inhibitor. In particular, disclosed is a compound represented by formula (II) or an isomer or pharmaceutically acceptable salt thereof. 

Thieno[2,3-c]pyridazin-4(1H)-one derivative and application thereof

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof. 

Thienodiazepine derivatives and application thereof

Disclosed is to a thiadiazole derivative and the uses thereof in preparing a drug for treating GLS1-associated diseases. Specifically disclosed is a derivative compound of formula (I), a tautomer thereof or a pharmaceutically acceptable composition thereof. 

Substituted 1,3,4-thiadiazoles as GLS1 inhibitors

Disclosed are a class of coumarin-like cyclic compounds as MEK inhibitors and pharmaceutical compositions comprising the compounds, and the use of same in the preparation of a drug for treating MEK-related diseases. Particularly disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof or tautomers thereof. 

Coumarin-like cyclic compound as MEK inhibitor and use thereof

Disclosed in the present application are a compound represented by formula (I), or a pharmaceutically acceptable salt, a tautomer thereof, a stereoisomer thereof, or a geometrical isomer thereof, and uses thereof in the preparation of drugs for treating or preventing multiple myeloma. 

Azetidine derivative

The present invention discloses a class of pyrrolidine derivatives as PPAR agonist, and their use for the treatment of some diseases of PPAR receptor-associated pathways (such as nonalcoholic steatohepatitis and concurrent fibrosis, insulin resistance, primary biliary cholangitis, dyslipidemia, hyperlipidemia, hypercholesterolemia, atherosclerosis, hypertriglyceridemia, cardiovascular disease, obesity or the like). In particular, the present invention discloses a compound represented by Formula (I) or a pharmaceutically acceptable salt thereof. 

Pyrrolidine derivatives as PPAR agonists

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

Compounds as rearranged during transfection (RET) inhibitors

Growing community of inventors

Shanghai, China

Zhen Gong